Monoclonal Mouse anti‑Human VIL1 / Villin Antibody (clone 5E3B2, IHC, WB) LS‑C669186
Monoclonal Mouse anti‑Human VIL1 / Villin Antibody (clone 5E3B2, IHC, WB) LS‑C669186
Antibody:
VIL1 / Villin Mouse anti-Human Monoclonal (5E3B2) Antibody
Application:
IHC, WB, ELISA
Format:
Unconjugated, Unmodified
Overview
Antibody:
VIL1 / Villin Mouse anti-Human Monoclonal (5E3B2) Antibody
Application:
IHC, WB, ELISA
Format:
Unconjugated, Unmodified
Specifications
Description
Villin antibody LS-C669186 is an unconjugated mouse monoclonal antibody to human Villin (VIL1). Validated for ELISA, IHC and WB.
Target
Human VIL1 / Villin
Synonyms
VIL1 | D2S1471 | Villin | Villin 1 | Villin-1 | VIL
Reactivity
Human
(tested or 100% immunogen sequence identity)
Clonality
IgG2b
Monoclonal
Conjugations
Unconjugated
Immunogen
Purified recombinant fragment of human VIL1 (AA: 1-209) expressed in E. Coli.
Applications
- IHC
- Western blot (1:100 - 1:500)
- ELISA (1:10000)
|
Performing IHC? See our complete line of Immunohistochemistry Reagents including antigen retrieval solutions, blocking agents
ABC Detection Kits and polymers, biotinylated secondary antibodies, substrates and more.
|
Presentation
PBS, 0.05% Sodium Azide
Storage
Short term: store at 4°C. Long term: store at -20°C.
Restrictions
For research use only. Intended for use by laboratory professionals.
Guarantee
This antibody carries the LSBio 100% Guarantee.
LSBio Guarantee
Featured Products
Species:
Human, Mouse
Applications:
ICC, Immunofluorescence, Western blot
Species:
Human
Applications:
IHC, IHC - Paraffin
Species:
Human, Mouse, Rat
Applications:
IHC, IHC - Paraffin, Western blot
Species:
Human, Mouse
Applications:
IHC, IHC - Paraffin, Western blot
Species:
Human, Mouse, Pig
Applications:
Western blot
Species:
Human, Mouse
Applications:
IHC, IHC - Paraffin, Western blot, Flow Cytometry
Request SDS/MSDS
To request an SDS/MSDS form for this product, please contact our Technical Support department at:
Technical.Support@LSBio.com
Requested From: United States
Date Requested: 12/21/2024